TARO Taro Pharmaceutical Industries Dashboard

Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products.

Company profile

Ticker

TARO

Exchange

NYSE

Website

www.taro.com

CEO

Uday Baldota

Location

Israel

Fiscal year end

Mar 31

Sector

Manufacturing > Pharmaceutical Preparation Manufacturing

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co • Allergan • Abbott Laboratories • Teva- Pharmaceutical Industries • Lilly(Eli) & Co • Bristol-Myers Squibb • Viatris • Warner Chilcott ...

SEC CIK

0000906338

Corporate docs

Articles of Incorporation & Bylaws

TARO stock data

S&P 500

1M 1Y 2Y 5Y

News

Pro users get this 30m faster

HC Wainwright & Co. Maintains Buy on Taro Pharmaceutical Indus, Raises Price Target to $82

28 Jul 21

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Taro Pharmaceutical Indus (NYSE:TARO) with a Buy and raises the price target from $80 to $82.

The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts

27 Jul 21

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 26)

Earnings Scheduled For July 27, 2021

27 Jul 21

Companies Reporting Before The Bell • Navios Maritime Partners (NYSE:NMM) is projected to report quarterly earnings at $2.93 per share on revenue of $146.03 million.

The Week Ahead In Biotech: Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More

25 Jul 21

A Peek Into The Markets: US Stock Futures Mixed Ahead Of Earnings, Economic Data

15 Jul 21

Press releases

Pro users get this 30m faster

Taro Provides Results for Quarter Ended June 30, 2021

27 Jul 21

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro") today provided unaudited financial results for the quarter ended June 30, 2021. Quarter ended June 30, 2021 Highlights - compared to Quarter ended June 30,

Taro to Announce First Quarter Results on July 27, 2021

20 Jul 21

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that it plans to release its financial results for the quarter ended June 30, 2021, after the close of market on Tuesday, July 27, 2021. The release will

Taro Announces Resignation of Chief Financial Officer

14 Jul 21

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro" or the "Company") announced today that it has accepted the resignation of its Chief Financial Officer, Daphne Huang, effective August 6, 2021. Ms. Huang is leaving

Taro Annual Report on Form 20-F Available For Fiscal Year Ended March 31, 2021

18 Jun 21

Taro Provides Results for the Year Ended March 31, 2021

19 May 21

Calendar

17 Jun 21

2 Aug 21

31 Mar 22

Financial summary

Financial statements Chart TARO financial data

Quarter (USD)	Mar 21	Mar 20	Mar 19	Mar 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Mar 21	Mar 20	Mar 19	Mar 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Institutional ownership Q1 2021

TARO institutional ownership history Ownership history

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

12.6% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	77	83	-7.2%
Opened positions	9	17	-47.1%
Closed positions	15	10	+50.0%
Increased positions	24	26	-7.7%
Reduced positions	23	22	+4.5%

13F shares	Current	Prev Q	Change
Total value	716.46M	369.03M	+94.1%
Total shares	4.76M	5.03M	-5.3%
Total puts	0	0
Total calls	0	0
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Renaissance Technologies	753.1K	$55.54M	-4.1%
FMR	623.92K	$46.01M	-8.1%
Krensavage Asset Management	547.64K	$40.39M	-1.1%
Dimensional Fund Advisors	502.49K	$37.06M	+4.9%
Brandes Investment Partners	405.47K	$30.33M	-1.6%
Acadian Asset Management	351.09K	$25.9M	-4.7%
BLK Blackrock	186.04K	$13.72M	+23.4%
Eversept Partners	164.38K	$12.12M	+8.0%
IVZ Invesco	161.8K	$11.93M	+6.3%
Hotchkis & Wiley Capital Management	109.55K	$8.08M	+8.5%

Largest transactions	Shares	Bought/sold	Change
Norges Bank	0	-118.75K	EXIT
NTRS Northern Trust	98.76K	-99.78K	-50.3%
FMR	623.92K	-54.82K	-8.1%
ARK Investment Management	78.63K	+50.61K	+180.6%
Nuveen Asset Management	54.46K	+40.04K	+277.6%
Charles Schwab Investment Management	0	-38.54K	EXIT
BLK Blackrock	186.04K	+35.26K	+23.4%
Renaissance Technologies	753.1K	-32K	-4.1%
MS Morgan Stanley	15.03K	-27.69K	-64.8%
Dimensional Fund Advisors	502.49K	+23.5K	+4.9%

Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Financial report summary

Competition

Akorn • Teligent

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: Accessible, Agarwal, Analyst, anesthesiologist, Aquinox, Arab, bellwether, Butalbital, certainty, CFA, chairperson, Chester, Cloderm, commerce, DOJ, Doxepin, East, entrepreneurial, essence, Fioricet, Flame, Florida, GC, heard, illegitimate, INSEAD, inserted, interstate, Michigan, Microbiology, Middle, MIGDALINSURANCE, MiMedx, misreporting, Moscow, municipal, Muscat, Neoleukin, nitrosamine, nurse, Polypid, quarantine, Ram, relocation, renowned, Scalp, scrutinize, Sernivo, simplifying, simultaneously, Sinequan, Sklice, span, Sri, St, stay, stint, subsidize, suspect, Taclonex, Tavaborole, twenty, Victoria, Vikash, Zyclara

Removed: Accenture, bb, bearing, began, Belgium, Benzoyl, BLA, calcium, career, Chantal, claimed, Clindamycin, codification, consulting, controversy, Dapsone, depreciate, disposed, dissolved, exportation, formally, gel, Glaze, grand, GSK, Hospira, IBM, Ikaria, inspector, Investigative, involvement, Ireland, Irish, jury, Kempac, LeBlanc, Mallinckrodt, manifested, modulator, Montreal, Mylan, negotiated, Peroxide, Phosphate, Polylab, positively, projected, promissory, recourse, reorganize, repealed, Rich, Richard, sovereign, subpoena, ULC, unfold, unutilized, vision

From filing 20-F 2021 FY